Severity of COVID-19 infection in ACEI/ARB users in specialty hospitals: A retrospective cohort study.
Angiotensin II receptor blocker
Angiotensin-converting enzyme inhibitor
COVID-19
Disease severity
Hospital admission
Mortality
Saudi Arabia
Journal
Journal of infection and public health
ISSN: 1876-035X
Titre abrégé: J Infect Public Health
Pays: England
ID NLM: 101487384
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
01
02
2021
revised:
03
03
2021
accepted:
07
03
2021
pubmed:
22
5
2021
medline:
9
6
2021
entrez:
21
5
2021
Statut:
ppublish
Résumé
The uncertainty about COVID-19 outcomes in angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) users continues with contradictory findings. This study aimed to determine the effect of ACEI/ARB use in patients with severe COVID-19. This retrospective cohort study was done in two Saudi public specialty hospitals designated as COVID-19 referral facilities. We included 354 patients with a confirmed diagnosis of COVID-19 between April and June 2020, of which 146 were ACEI/ARB users and 208 were non-ACEI/ARB users. Controlling for confounders, we conducted multivariate logistic regression and sensitivity analyses using propensity score matching (PSM) and Inverse propensity score weighting (IPSW) for high-risk patient subsets. Compared to non-ACEI/ARB users, ACEI/ARB users had an eight-fold higher risk of developing critical or severe COVID-19 (OR = 8.25, 95%CI = 3.32-20.53); a nearly 7-fold higher risk of intensive care unit (ICU) admission (OR = 6.76, 95%CI = 2.88-15.89) and a nearly 5-fold higher risk of requiring noninvasive ventilation (OR = 4.77,95%CI = 2.15-10.55). Patients with diabetes, hypertension, and/or renal disease had a five-fold higher risk of severe COVID-19 disease (OR = 5.40,95%CI = 2.0-14.54]. These results were confirmed in the PSM and IPSW analyses. In general, but especially among patients with hypertension, diabetes, and/or renal disease, ACEI/ARB use is associated with a significantly higher risk of severe or critical COVID-19 disease, and ICU care.
Sections du résumé
BACKGROUND
BACKGROUND
The uncertainty about COVID-19 outcomes in angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) users continues with contradictory findings. This study aimed to determine the effect of ACEI/ARB use in patients with severe COVID-19.
METHODS
METHODS
This retrospective cohort study was done in two Saudi public specialty hospitals designated as COVID-19 referral facilities. We included 354 patients with a confirmed diagnosis of COVID-19 between April and June 2020, of which 146 were ACEI/ARB users and 208 were non-ACEI/ARB users. Controlling for confounders, we conducted multivariate logistic regression and sensitivity analyses using propensity score matching (PSM) and Inverse propensity score weighting (IPSW) for high-risk patient subsets.
RESULTS
RESULTS
Compared to non-ACEI/ARB users, ACEI/ARB users had an eight-fold higher risk of developing critical or severe COVID-19 (OR = 8.25, 95%CI = 3.32-20.53); a nearly 7-fold higher risk of intensive care unit (ICU) admission (OR = 6.76, 95%CI = 2.88-15.89) and a nearly 5-fold higher risk of requiring noninvasive ventilation (OR = 4.77,95%CI = 2.15-10.55). Patients with diabetes, hypertension, and/or renal disease had a five-fold higher risk of severe COVID-19 disease (OR = 5.40,95%CI = 2.0-14.54]. These results were confirmed in the PSM and IPSW analyses.
CONCLUSION
CONCLUSIONS
In general, but especially among patients with hypertension, diabetes, and/or renal disease, ACEI/ARB use is associated with a significantly higher risk of severe or critical COVID-19 disease, and ICU care.
Identifiants
pubmed: 34020213
pii: S1876-0341(21)00069-1
doi: 10.1016/j.jiph.2021.03.004
pmc: PMC7986317
pii:
doi:
Substances chimiques
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
726-733Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
Am J Hypertens. 2020 Oct 21;33(10):944-948
pubmed: 32511678
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Emerg Microbes Infect. 2020 Dec;9(1):757-760
pubmed: 32228222
Eur J Clin Invest. 2007 Jun;37(6):483-91
pubmed: 17537156
J Family Community Med. 2017 Sep-Dec;24(3):156-163
pubmed: 28932160
J Am Coll Cardiol. 1993 Nov 15;22(6):1557-63
pubmed: 8227822
Clin Chim Acta. 2008 Feb;388(1-2):46-50
pubmed: 17977523
Heart. 2020 Oct;106(19):1503-1511
pubmed: 32737124
Clin Chem Lab Med. 2020 Jun 29;58(9):1415-1422
pubmed: 32598305
Eur Heart J Cardiovasc Pharmacother. 2021 Mar 15;7(2):148-157
pubmed: 32542337
Exp Mol Med. 2003 Dec 31;35(6):545-9
pubmed: 14749533
Pharmacol Res. 2020 Oct;160:105053
pubmed: 32619721
Travel Med Infect Dis. 2020 May - Jun;35:101711
pubmed: 32360326
Clin Exp Hypertens. 2020 Nov 16;42(8):738-742
pubmed: 32569491
PLoS One. 2019 Aug 20;14(8):e0221248
pubmed: 31430320
Int J Health Sci (Qassim). 2015 Jul;9(3):V-VI
pubmed: 26609301
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Am J Hypertens. 1994 Aug;7(8):759-62
pubmed: 7986468
Obesity (Silver Spring). 2020 Jul;28(7):1175
pubmed: 32314861
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1380-1388
pubmed: 32275452
Intensive Care Med. 2020 Apr;46(4):586-590
pubmed: 32125455
J Hypertens. 2005 Mar;23(3):463-73
pubmed: 15716683
Rev Med Virol. 2018 May;28(3):e1977
pubmed: 29664167
Curr Diabetes Rev. 2017;13(1):59-64
pubmed: 26813972
Biomed Rep. 2017 Jul;7(1):56-60
pubmed: 28685061
JAMA Cardiol. 2020 Sep 1;5(9):1020-1026
pubmed: 32936273
Eur Heart J Cardiovasc Pharmacother. 2021 Sep 21;7(5):426-434
pubmed: 32531040
Eur J Heart Fail. 2020 Jun;22(6):967-974
pubmed: 32485082
Arch Iran Med. 2008 Jan;11(1):3-9
pubmed: 18154415
Pharmacol Res. 2020 Aug;158:104927
pubmed: 32422341
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Front Med (Lausanne). 2020 Apr 30;7:190
pubmed: 32426363
Lancet Respir Med. 2020 Apr;8(4):e21
pubmed: 32171062
J Hum Hypertens. 2017 Jun;31(6):373-375
pubmed: 28332509
Korean J Anesthesiol. 2018 Oct;71(5):353-360
pubmed: 30157585
Ann Transl Med. 2020 Apr;8(7):430
pubmed: 32395474
Clin Chim Acta. 2020 Sep;508:254-266
pubmed: 32474009
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
BMJ. 2019 Oct 23;367:l5657
pubmed: 31645336
J Renin Angiotensin Aldosterone Syst. 2015 Dec;16(4):1240-4
pubmed: 25237167
Drugs Ther Perspect. 2020;36(8):347-350
pubmed: 32837189
J Hypertens. 2020 May;38(5):781-782
pubmed: 32195824
Hypertension. 2020 Jul;76(1):51-58
pubmed: 32348166